Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0018.

Trial Profile

Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0018.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2018

At a glance

  • Drugs Fexapotide (Primary)
  • Indications Benign prostatic hyperplasia
  • Focus Registrational; Therapeutic Use
  • Acronyms NEXUS-2
  • Most Recent Events

    • 01 Mar 2018 According to a Nymox Pharmaceutical Corporation media release, results from this trial will be presented at the Annual Meeting of the American Urological Association in Mar 2018.
    • 05 Feb 2018 According to a Nymox Pharmaceutical Corporation media relase, company will submitt an NDA for Fexapotide Triflutate for the treatment of BPH to the US FDA in 2018.
    • 30 Jan 2018 According to a Nymox Pharmaceutical Corporation media release, results from four phase III trials (NX02-0017, NX02-0018, NX02-0020 and NX02-0022) have been published in the World Journal of Urology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top